Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Altered Bile Acids and Pouch Microbiota Composition in Patients With Chronic Pouchitis.
Inflamm Bowel Dis
March 2025
Division of Gastroenterology & Hepatology, Mayo Clinic, Rochester, MN, USA.
Comment on "Hypospadias risk associated with chronic hypertension during pregnancy: A systematic review and meta-analysis".
J Pediatr Urol
February 2025
Department of Paediatrics, Dr. D. Y. Patil Medical College Hospital and Research Centre, Dr. D. Y. Patil Vidyapeeth (Deemed-to-be-University), Pimpri, Pune, 411018, Maharashtra, India; Department of Public Health Dentistry, Dr. D. Y. Patil Medical College Hospital and Research Centre, Dr. D. Y. Patil Vidyapeeth (Deemed-to-be-University), Pimpri, Pune, 411018, Maharashtra, India. Electronic address:
Reply to Post-traumatic Stress Disorder: A Major Source of Concern Comment on "Epidemiology of Post-traumatic Stress Disorder in Iranian Population From 2019 to 2024: A Systematic Review and Meta-analysis".
Arch Iran Med
February 2025
Pain Research Center, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.
Potential benefits of GLP-1 receptor agonist in dialysis patients with type 2 diabetes: the need for comprehensive pharmacokinetic and hemodialysis analyses.
Cardiovasc Diabetol
March 2025
Division of Nephrology, Department of Internal Medicine, National Cheng Kung UniversityHospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan.
The 2022 KDIGO guideline for diabetes management in patients with chronic kidney disease (CKD) had endorsed the use of GLP-1 receptor agonists (GLP-1RAs) for patients with CKD and type 2 diabetes who did not achieve optimal glycemic target with maximally tolerated metformin and sodium-glucose co-transporter-2 (SGLT-2) inhibitor. Our study revealed the potential benefits of GLP-1RAs in patients with dialysis-requiring acute kidney disease possibly owing to pleiotropic effects of the medicine. Nonetheless, pharmacokinetics and dialysis dose were omitted in our subgroup analyses.
View Article and Find Full Text PDFDiagnosis and Oral Sirolimus Treatment of Fibro-Adipose Vascular Anomaly in Pediatric Patients: A Case Series and Comprehensive Review.
Paediatr Drugs
March 2025
Department of Dermatology, Beijing Children's Hospital, National Center for Children's Health, Capital Medical University, No. 56 Nanlishi Road, Xi Cheng District, Beijing, 100045, China.
Background: Fibro-adipose vascular anomaly (FAVA) is a rare and complex vascular malformation that, to date, has hardly been studied, especially in children. The diagnosis and management of FAVA is complicated, and no treatment guidelines have yet been published.
Objectives: This study aimed to analyze the clinical manifestations and diagnostic and genetic evidence of FAVA and to explore safe and effective treatment with sirolimus in pediatric patients.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!